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Exposure to solar ultraviolet B radiation during the sum-
mer months is the main source of vitamin D (VD) for 
people living in northern latitudes. The aim of this study 
was to determine whether artificial narrowband ultra-
violet B (NB-UVB) whole-body exposures could maintain 
VD levels in winter. The intervention group received 2 
standard erythema doses (SEDs) of NB-UVB exposures 
every second week from October 2013 to April 2014. In 
October 2013 serum 25-hydroxyvitamin D concentra-
tions were 78.3 nmol/l in the intervention group (n = 16) 
and 76.8 nmol/l in the control group (n = 18). By April 
2014 the concentrations had increased by 11.7 nmol/l 
(p = 0.029) in the intervention group and decreased by 
11.1 nmol/l (p = 0.022) in the control group. The base-
line VD concentration showed a negative correlation 
(p = 0.012) with body mass index (BMI). In conclusion, a 
suberythemal NB-UVB dose of 2 SED every second week 
maintains and even increases serum VD concentrations 
during the winter. A high BMI seems to predispose sub-
jects to low levels of VD. Key words: 25-hydroxyvitamin D; 
ultraviolet B; narrow-band ultraviolet B; body mass index.
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Vitamin D (VD) insufficiency is a worldwide issue (1). 
VD is synthesized from 7-dehydrocholesterol in response 
to ultraviolet B (UVB) radiation and its key role is in 
adjusting the serum calcium level to enable metabolic 
functions, signal transduction and neuromuscular acti-
vity (2). VD insufficiency has been linked to chronic 
skeletal (3) and extra-skeletal diseases, such as obesity 
and type 2 diabetes mellitus (4, 5). The best indicator 
of VD status is its circulating form, 25-hydroxyvitamin 
D [25(OH)D] (2). Levels above 50 nmol/l are thought 
to be sufficient for calcium and bone homeostasis, but 
the optimal level for extra-skeletal effects is unclear 
(6). The Institute of Medicine (Washington DC, USA) 
recommends a dietary intake of VD supplements of 15 
µg daily for people aged 1–70 years and 20 µg daily for 
those older than 70 years (7). In addition to VD supp-
lements, artificial ultraviolet B (UVB) light treatments 
increase VD concentrations (8). Narrowband ultraviolet 
B (NB-UVB) exposures given 3 times a week increase 
serum 25(OH)D concentrations even more than does 20 
µg or 40 µg oral cholecalciferol daily (9, 10). Bogh et 
al. (11) showed that 1 standard erythema dose (SED) of 
broadband ultraviolet B (BB-UVB) every second week 
can be used to maintain serum 25(OH)D concentrations 
during the winter (11). On the other hand, as NB-UVB 
is better tolerated (12), widely used (13), and provides 
a higher vitamin D action spectrum-weighted irradiance 
dose (14), we examined its ability to maintain summer 
levels of vitamin D throughout the winter period.
MATERIALS AND METHODS
Subjects
Thirty-seven healthy volunteers were randomized to an interven-
tion group (n = 18) or a control group (n = 19). Inclusion criteria 
were: age 18 years or older; and avoidance of solarium visits, 
phototherapy, sunny holidays and vitamin D supplementation 
during a 1-month washout period prior to the trial and during it. 
Exclusion criteria were: pregnancy, skin disease, previous skin 
cancer, intake of photosensitizing drugs; and Fitzpatrick’s skin 
reactive type 1 (15). Recruitment began on 1 September 2013 
and the trial was carried out at the Department of Dermatology 
of Tampere University Hospital from 7 October 2013 to 5 May 
2014. The principal investigator assessed the skin types of the 
volunteers. VD intake at the onset was estimated by means of 
a 3-day food frequency questionnaire. Altogether 34 subjects 
completed the trial (Table I). Two intervention subjects were 
disqualified for failing to follow the irradiation schedule and one 
control subject was disqualified for taking VD supplements. All 
3 were excluded from the analyses. The protocol was approved 
by the ethics committee of Tampere University Hospital, and all 
the volunteers gave their informed consent in advance. 
Randomization and sample size calculation
Volunteers were randomized to the intervention and control 
groups in blocks of 2 using a web-based validated program (Re-
search Randomizer (http://www.randomizer.org)). The primary 
investigator randomized and enrolled all the participants. The 
trial was designed to show an inter-group difference in 25(OH)
D of at least 12 nmol/l, with an α-value of 0.05 and a β-value of 
0.90. An assumed standard deviation (SD) of 9 nmol/l for the 
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25(OH)D analyses at 50 nmol/l was used. Thus, it was considered 
necessary that 12 volunteers per group should complete the trial.
Narrowband ultraviolet B treatment
The intervention group received a total of 13 NB-UVB whole-
body exposures, given every other week for 24 weeks with 
a Waldmann UV 7002 cabin equipped with 42 TL01 tubes 
(Schulze & Böhm, Brühl, Germany). The first NB-UVB non-
weighted total UV dose was 170 mJ/cm2 (1 SED), which was 
subsequently increased to 340 mJ/cm2 (2 SED). One SED is 
equivalent to an erythemal effective radiant exposure of 10 mJ/
cm2 CIE (16). The cabin was calibrated by the Nuclear Safety 
Authority of Finland using an Ocean Optics S2000 spectrora-
diometer. After correction for stray light and other systematic 
errors, the estimated measurement uncertainty (2σ) of the Ocean 
Optics S2000 is 14% (17) and the measurements are traceable 
to the National Institute of Standards and Technology, USA. 
Previously measured lamp spectra were used for the NB-UVB 
(TL01) and BB-UVB (Waldmann UV6) dose calculations (18).
Serum 25-hydroxyvitamin D and parathyroid hormone measurements 
Blood samples for 25(OH)D analyses were drawn at the onset, 
and at weeks 6, 14, 20, 26 and 30. During the intervention 
period the samples of the intervention group were taken just 
before the scheduled exposure to UVB. The samples were 
centrifuged and plasma was stored at –20°C and analysed for 
25(OH)D by enzyme immunoassay (Roche Diagnostics, Mann-
heim, Germany). Plasma parathyroid hormone (PTH) samples 
were taken at the onset of the trial and at 14 weeks. Blood was 
collected into ethylenediaminetetraacetic acid (EDTA) tubes, 
centrifuged and analysed by immunochemiluminometric assay. 
Statistical analysis
Confidence intervals (95% CI) were obtained by bias-corrected 
bootstrapping (5,000 replications). Statistical comparisons were 
made using the analysis of t-test co-variance (ANCOVA). In 
the case of violation of the assumptions (e.g. non-normality) 
a bootstrap-type test was used. Longitudinal measures for 
continuous outcomes were analysed using a bootstrap-type 
generalized estimating equations (GEE) model, the GEE having 
been developed as an extension of the general linear model for 
analysing longitudinal and other correlated data. GEE models 
take into account the correlation between repeated measure-
ments in the same subject, they do not require complete data, 
and a fit can be achieved even when observations for some 
individuals are lacking at certain time-points. No adjustment 
was made for multiple testing. When comparing the increases 
in VD concentrations, the model was adjusted for the baseline 
value, body mass index (BMI) and Fitzpatrick’s skin type. 
Pearson’s χ2-test was used when comparing nominal data. 
The STATA 13.1, StataCorp LP (College Station, TX, USA) 
statistical package was used for the analyses.
RESULTS
Vitamin D intake and NB-UVB exposures
The mean ± SD daily VD intake at onset was 7.0 ± 3.7 
µg in the intervention group and 6.7 ± 2.2 µg in the 
control group (p = 0.78) (Table I). The intervention 
group received 13 NB-UVB exposures over 24 weeks, 
implying a cumulative NB-UVB dose of 25 SED, 
which corresponds to a physical dose of 4.25 J/cm2. 
No adverse effects were detected.
Serum 25-hydroxyvitamin D concentrations
The mean baseline serum VD concentration in October 
was 78.3 nmol/l in the intervention group and 76.8 nmol/l 
in the control group (Table II, Fig. 1) showing a mode-
rate negative correlation with BMI (r = –0.43, p = 0.012). 
The mean ± SD concentrations in the intervention group 
peaked at 104.5 ± 40.2 nmol/l in February, i.e. in week 
20 (Fig. 1), and had a mean increase of 11.7 nmol/l 
(p = 0.029) by the end of the intervention period, in April 
(week 26), at which point the mean for the control group 
had decreased by 11.1 nmol/l (p = 0.022, Fig. 1, Table 
II). The difference between the groups was statistically 
highly significant (p < 0.001) when adjusted for the ba-
seline value, BMI and Fitzpatrick’s skin type. During 
the 1-month follow-up period the mean concentration of 
VD in the intervention group decreased by 10.6 nmol/l 
(p < 0.001) and that in the control group by 2.7 nmol/l 
(p = 0.18; Fig. 1, Table II).
Parathyroid hormone 
concentrations
The mean ± SD initial PTH 
levels were 3.8 ± 1.1 pmol/l 
in the intervention group and 
4.2 ± 1.2 pmol/l in the control 
group (p = 0.32), while those at 
week 14 were 3.7 ± 1.4 pmol/l 
and 4.7 ± 1.8 pmol/l, respecti-
vely (p = 0.11) (Table I).
Table I. Demographics, vitamin D intake and plasma parathyroid 
hormone concentrations at baseline in the narrow-band ultraviolet 




n = 18 p-value
Males/females, n 3/13 1/17 0.32
Age, years, mean (range) 35 (21–61) 36 (20 –61) 0.76
BMI, kg/m2, mean ± SD 23.0 ± 1.9 25.2 ± 3.4 0.029
Fitzpatrick’s skin type II/III/IV, n 8/7/1 8/10/0 0.61
Vitamin D intake, µg/day, mean ± SD 7.0 ± 3.7 6.7 ± 2.2 0.78
Parathyroid hormone, pmol/l, mean ± SD 3.8 ± 1.1 4.2 ± 1.2 0.32
BMI: body mass index; SD: standard deviation.
Table II. Serum 25-hydroxyvitamin D concentrations in the narrow-band ultraviolet B (NB-
UVB)-treated and control groups at baseline and at the end of the intervention period (week 26)






Baseline (October 2013), mean ± SD 78.3 ± 36.1 76.8 ± 26.6 0.90a
Week 26 (April 2014), mean ± SD 88.7 ± 29.2 65.8 ± 23.9 0.019a
Change from baseline to week 26, mean (95% CI) 11.7 (1.9 –20.0)b –11.1 (–19.4 to –2.7)c 0.0017a
Change from week 26 to 30, mean (95% CI) –10.6 (–15.1 to –5.9)d –2.7 (–6.1–0.8)e 0.015a
aNot adjusted; bp = 0.029; cp = 0.022; dp < 0.001; ep = 0.18.
SD: standard deviation; 95% CI: 95% confidence interval.
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DISCUSSION 
The results of this study show that an artificial NB-UVB 
exposure of 2 SED every second week maintained VD 
concentrations throughout the winter, whereas levels in 
the control group decreased. No adverse effects were 
observed. The NB-UVB dose was small, given that an 
average Dane receives 1.5 SED of solar UV radiation 
daily in July (19). Bogh et al. (11) have shown that a 
BB-UVB exposure of 1 SED every second week will 
maintain summer levels of VD. They gave 9 BB-UVB 
exposures over 16 weeks and observed a non-significant 
decrease of 4.7 nmol/l from the baseline concentration of 
VD of 72.0 nmol/l. In the present trial we gave 13 NB-
UVB exposures over 24 weeks and achieved a significant 
increase of 11.7 nmol/l over a baseline concentration 
of VD of 78.3 nmol/l. The dose (2 SED vs. 1 SED) 
and the length of exposure (24 vs. 16 weeks) seem to 
be the major reasons for the better VD response in our 
volunteers, although the fact that the vitamin D action 
spectrum-weighted irradiance dose (14) for an exposure 
of 1 SED is higher with NB-UVB (23 mJ/cm2 CIE) than 
with BB-UVB (16 mJ/cm2 CIE) may also have had an 
effect. It should be noted that the highest concentration 
of VD was observed at week 20 (Fig. 1), before the last 
3 NB-UVB exposures were given. The subsequent de-
crease in concentration may have been due to negative 
feedback in the 25(OH)D system (20).
The administration of UVB irradiation over a long 
period of time raises a question regarding the potential 
risks related to UV-induced immunosuppression. The 
human action spectrum for immunosuppression peaks 
at UVA and UVB wavelengths, as measured by UV-
induced suppres sion of elicitation of delayed or contact 
type hypersensitivity (CHS) to nickel (21, 22). The most 
sensitive UVA wavelength is 370 nm, where the minimum 
immunosuppressive physical dose is 409.4 mJ/cm2 (21). In 
the present trial a 1 SED dose was equal to an integrated 
non-weighted dose of 11 mJ/cm2 between 360 and 390 nm 
for both NB-UVB and BB-UVB lamps, which is below 
the immunosuppressive dose. In the UVB range immuno-
suppression peaks at 300 nm and no immunosuppression 
has been recorded at 322 nm (22). With a 1 SED dose of 
NB-UVB or BB-UVB the minimum immunosuppressive 
dose is not exceeded, but it could be exceeded with a 2 
SED dose of either NB-UVB or BB-UVB. However, sup-
pression of the recall type (efferent) immunity, such as the 
patch-testing existing nickel allergy, is just one possible 
end-point of the immune response. Other potentially more 
relevant end-points are the suppression of the induction 
of either local (CHS) or systemic delayed type hypersen-
sitivity (the afferent immunity) (23, 24). Even though no 
association between NB-UVB treatment and skin cancer 
has been observed (25), there are no safe limits for photo-
therapy. What is “safe” for one individual is not safe for 
another (26, 27). Both UVB and UVA cause signature 
mutations in DNA, and UVA wavelengths promote photo-
aging. As regards the mutagenic potential of NB-UVB and 
BB-UVB, they appear to be equal (28). 
We found a moderate negative correlation between 
BMI and baseline VD status in our volunteers. A meta-
analysis has confirmed the occurrence of low VD con-
centrations among obese subjects, suggesting that the 
reason for this may be volumetric dilution of 25(OH)
D in the fat tissue (29). A high BMI therefore seems to 
predispose subjects to VD insufficiency, which in turn 
increases the risk of contracting VD-related diseases 
(3–5). The dietary VD intake was 7.0 µg in the inter-
vention group and 6.7 µg in the control group. These 
intakes were approximately the same as in our previous 
study with healthy subjects (8), but remained lower than 
in the recent national survey carried out in Finland (30). 
Only a few of the present volunteers were receiving the 
estimated average requirement of 10 µg dietary VD 
daily, and none had reached the recommended dietary 
allowance of 15 µg (7). It seems that an additional 10 
µg VD supplement is needed to ensure adequate VD 
status in the adult population (7, 31).
We have shown previously that regular NB-UVB 
exposures increase serum VD concentrations more than 
20 µg of oral cholecalciferol daily (9). In addition, NB-
UVB exposures increased the mean VD concentration 
by as much as 58% in patients with psoriasis who were 
receiving a 20 µg oral cholecalciferol supplement daily 
(32). Lagunova et al. (33) compared the effect of VD 
supplementation (50 µg oral cholecalciferol daily) and 
10 UVB exposures to a total dose of 23.8 SED on VD 
concentration in a 1-month study. Both interventions 
increased serum 25(OH)D concentrations similarly, by 
Time, weeks
































Fig. 1. 25-Hydroxyvitamin D concentrations in the narrow-band ultraviolet 
B (NB-UVB)-treated and control groups during the intervention (weeks 
0–26) and follow-up periods (weeks 26–30).
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20–25 nmol/l. The total UVB dose was comparable to 
the 25 SEDs given in our study, but the intervention 
period was only 5 weeks compared with our 24 weeks. 
In the following commentary, UV dose-response studies 
with more careful and possibly safer exposure protocol 
were warranted (34). The strengths of our study are the 
randomized and controlled design, the long time-frame 
covering all winter, and the similarity of the groups. A 
limitation of our study is the need to standardize further 
the analytical methods for 25(OH)D, as suggested by 
Volmer et al. (35). 
Our goal was to examine the capacity of low-dose NB-
UVB exposures to maintain VD concentrations during 
the winter. The results confirmed that the 2 SED dose 
given every second week from October to April was 
enough to maintain the baseline concentrations of VD 
and even to increase them, suggesting that a NB-UVB 
dose of 1 SED might be appropriate for this purpose. A 
parallel comparison of continuous NB-UVB exposures 
and the recommended oral VD supplementation of 10 
µg daily during the winter should be carried out (7, 31).
In conclusion, a suberythemal dose of NB-UVB of 
2 SED given to healthy subjects every second week 
over the winter months can maintain and even increase 
post-summer VD concentrations.
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